tbuckley/cabot-search huggingface dataset:
Patterns and costs of hospital-based cancer care in the last year of life: A national data linkage study in England.
Authors: Xhyljeta Luta, Katharina Diernberger, Joanna Bowden, Joanne Droney, Peter S Hall, Joachim Marti
Journal: Journal of Clinical Oncology (2021)

e18769 Background: Delivery of high quality cancer care is associated with rising costs, both in earlier stages of the illness trajectory and at the end of life. A significant portion of the costs and health care utilisation occurs in the last year of life. Most publications to date have focused on costs in hospital. Little is known about the costs of care for cancer patients across the entire health service. The aim was to examine primary, secondary and acute health care utilisation and cost in the last 12 months of life and how these differ by cancer diagnosis and other patient characteristics among decedent patients aged 60 and over. Methods: We conducted a retrospective cohort study of people aged 60 years and over (N=26,077) who died in England between 2010 and 2017. We used routinely collected and linked data from primary care (Clinical Practice Research Datalink (CPRD) secondary and acute care, (Hospital Episode Statistics (HES), and death data (Office for National Statistics (ONS)). This provided a nationally representative sample of the English population. We analysed of healthcare utilisation and resource use amongst decedents by gender, primary cause of death, age, geography, socio-economic status and comorbidities. Results: Overall, 90.2 % of the cancer decedents were admitted in the hospital at least once in the last 12 months of life. About 50% of patients we admitted to hospital in the last month of life with 37.6 being admitted to the hospital more than once in the last month of life. The health care utilisation and costs increased sharply in the last month of life. life. The mean number of hospital admissions in the last year of life was 3.7 (SD, 5.8). Those dying of haematological cancers (N=2093) had highest number of hospital admissions (mean:7.2, SD:10.8) and longer average hospital stay (mean:36.7, SD:33.0) (mean:12.0, SD:14.4). Use of outpatient services was highest in the group dying of haematological cancers (mean:12.0, SD:14.4) whereas those dying of prostate cancer (N= 2197) had higher number of emergency (mean:2.0, SD: 1.9) and GP visits (mean:30.8, SD: 20.7). Healthcare costs were highest among haematological cancers and lowest among those dying of breast cancer. Proximity to death and comorbidities were the main contributors of end-of-life care health care utilisation and costs. Conclusions: This study uses large linked datasets (linked to the whole spectrum of hospital episode statistics) providing a comprehensive picture of healthcare services accessed by cancer patients at end of life in England. There is significant variation in use and cost of care for cancer patients in the last year and month of life. Further analysis of variation according to hospice, palliative, and social care service provision may identify strategies to address this variation.
Authors’ Reply
Authors: Cal H. Robinson, Nivethika Jeyakumar, Ron Wald, Michael Zappitelli, Rahul Chanchlani
Journal: Journal of the American Society of Nephrology (2021)

We thank Zhao et al. [1][1] and Wei[2][2] for their interest in our manuscript, "Long-term kidney outcomes following childhood acute kidney injury receiving dialysis: A population-based cohort study,"[3][3] and for providing thoughtful feedback. The letter from Zhao et al. [1][1] correctly
Europe must come together to confront omicron
Journal: BMJ (2022)

Europe must come together to confront omicronThe SARS-CoV-2 omicron variant is spreading rapidly in Europe, even in countries with high levels of vaccination, including those that have moved quickly with booster vaccinations. 1 2We write as health professionals and researchers from across Europe to call for concerted European action to address the immediate threat and to move rapidly to develop joint plans to tackle future variants of concern effectively.EU Member States have accepted the principle of a European Health Union and have put in place measures to create a Health Emergency Preparedness and Response Authority. 3They now need to show that they can work together in ways that they have not always done before.
Colon Cancer
Authors: _ _
Journal: Journal of the National Comprehensive Cancer Network (2007)

Colorectal cancer is the third most frequently diagnosed cancer in men and women in the United States. An estimated 112,340 new cases of colon cancer will occur in 2007 and an estimated 52,180 people will die from colon and rectal cancer in the same year. Despite these statistics, mortality from colon cancer has decreased over the past 30 years, possibly because of earlier diagnosis through screening and better treatment modalities. These guidelines begin with the clinical presentation of the patient to the primary care physician or gastroenterologist and address diagnosis, pathologic staging, surgical management, adjuvant treatment, management of recurrent and metastatic disease, and patient surveillance. For the most recent version of the guidelines, please visit NCCN.org
Retrograde fallopian tube transport
Authors: C. J. Pauerstein
Journal: JAMA (1985)

Dr Schwartz and colleagues<sup>1</sup>have reported vernix caseosa peritonitis after premature rupture of the membranes during the 25th week of pregnancy. They postulate that the vernix was delivered to the peritoneal cavity via retrograde transport through the fallopian tubes. The concept of retrograde transport through the fallopian tubes is not new. Various investigations dating back to 1880 have demonstrated that small particles such as india ink, carbon, starch, and talc can be transported through the oviduct in both directions at all times in the estrus or menstrual cycle.<sup>2</sup>In performing its normal physiological function, the oviduct must transport the sperm toward the ovary and the ovum toward the uterus. Although the mechanism of the transport of sperm from the uterus to the fimbriated end of the oviduct is not clearly defined, Eddy et al<sup>3</sup>clearly demonstrated that in the rabbit oviduct, cilia are not essential to the
CircRTN4 promotes pancreatic cancer progression through a novel CircRNA-miRNA-lncRNA pathway and stabilizing epithelial-mesenchymal transition protein
Authors: Chi Hin Wong, Ut Kei Lou, Frederic Khe-Cheong Fung, Joanna H. M. Tong, Chang-hua Zhang, Ka-Fai To, Stephen Lam Chan, Yangchao Chen
Journal: Molecular Cancer (2022)

Circular RNAs (circRNAs) play important roles in many biological processes. However, the detailed mechanism underlying the critical roles of circRNAs in cancer remains largely unexplored. We aim to explore the molecular mechanisms of circRTN4 with critical roles in pancreatic ductal adenocarcinoma (PDAC).CircRTN4 expression level was examined in PDAC primary tumors. The oncogenic roles of circRTN4 in PDAC tumor growth and metastasis were studied in mouse tumor models. Bioinformatics analysis, luciferase assay and miRNA pulldown assay were performed to study the novel circRTN4-miRNA-lncRNA pathway. To identify circRTN4-interacting proteins, we performed circRNA-pulldown and mass spectrometry in PDAC cells. Protein stability assay and 3-Dimensional structure modeling were performed to reveal the role of circRTN4 in stabilizing RAB11FIP1.CircRTN4 was significantly upregulated in primary tumors from PDAC patients. In vitro and in vivo functional studies revealed that circRTN4 promoted PDAC tumor growth and liver metastasis. Mechanistically, circRTN4 interacted with tumor suppressor miR-497-5p in PDAC cells. CircRTN4 knockdown upregulated miR-497-5p to inhibit the oncogenic lncRNA HOTTIP expression. Furthermore, we identified critical circRTN4-intercting proteins by circRNA-pulldown in PDAC cells. CircRTN4 interacted with important epithelial-mesenchymal transition (EMT)- driver RAB11FIP1 to block its ubiquitination site. We found that circRTN4 knockdown promoted the degradation of RAB11FIP1 by increasing its ubiquitination. Also, circRTN4 knockdown inhibited the expression of RAB11FIP1-regulating EMT-markers Slug, Snai1, Twist, Zeb1 and N-cadherin in PDAC.The upregulated circRTN4 promotes tumor growth and liver metastasis in PDAC through the novel circRTN4-miR-497-5p-HOTTIP pathway. Also, circRTN4 stabilizes RAB11FIP1 to contribute EMT.
Low Iron Promotes Megakaryocytic Commitment of Megakaryocytic-Erythroid Progenitors in Human and Mice
Authors: Juliana Xavier-Ferrucio, Xiuqi Li, Vanessa Scanlon, Ping-Xia Zhang, Nadia Ayala-Lopez, Toma Tebaldi, Stephanie Halene, Karin E. Finberg, Diane S. Krause
Journal: Blood (2018)
Die Specifische Percutanbehandlung der Tuberkulose mit dem Petruschkyschen Tuberkulinliniment.
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Stenting in small coronary arteries (SISCA): A randomized comparison of heparin coated beStent and balloon angioplasty Rasmus Moer, Yngvar Myreng, Per Albertsson, P�l Albertsson, P�l Gunnes, Bo Lindvall, Rune Wiseth, Per M�lstad, Kjetil Ytre-Arne, Svein Golf. Feiring Heart Clinic, Feiring, Norway
Journal: Journal of the American College of Cardiology (2001)
Quality of life one year after invasive intervention in unstable coronary artery disease: Results from the FRISC II invasive trial Magnus Janzon, Lars-pke Levin, Eva Swahn, FRISC II investigators. Institution of Medicine and Care, Link�ping University, Link�ping, Sweden, CMT, Center for Medical Technology Assessment, Link�ping University, Link�ping, Sweden
Journal: Journal of the American College of Cardiology (2001)
Niacin plus simvastatin protect against atherosclerosis progression and clinical events in CAD patients with low HDLc and diabetes mellitus or impaired fasting glucose Josiah S. Morse, B. Greg Brown, Xue-Qiao Zhao, Lloyd Fisher, Alan Chait, Alice Dowdy, Leny Serafini, Ellen Huss-Frechette, Debbie DeAngelis, Jiri Frohllich, John Albers. University of Washington, Seattle, WA, University of British Columbia, Vancouver, BC, Canada
Journal: Journal of the American College of Cardiology (2001)
TCT-707 Drug-Eluting Stents for the Treatment of Left Main Coronary Artery Disease with Bifurcated Lesions: A Comparison with Sirolimus, Paclitaxel, Zotarolimus (Endeavor Resolute), BiolimusA9, EPC Capture and Everolimus-Eluting Stent: Multicenter Registry in Asia
Authors: Sunao Nakamura, Hisao Ogawa, Jang-Ho Bae, Yeo Cahyadi, Wasan Udayachalerm, Damras Tresukosol, Sudaratana Tansuphaswadikul
Journal: Journal of the American College of Cardiology (2012)
COPYRIGHTED.
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CARDIAC POSITRON EMISSION TOMOGRAPHY ENHANCES PROGNOSTIC ASSESSMENTS OF PATIENTS WITH SUSPECTED CARDIAC SARCOID
Authors: Ron Blankstein, Masanao Naya, Micahel Osborne, Chun Kim, Venkatesh Murthy, Raymond Kwong, Kazemian Pedram, Michifumi Tokuda, Jon Hainer, William Stevenson, Sharmila Dorbala, Marcelo Di Carli
Journal: Journal of the American College of Cardiology (2012)
A Practical Treatise on Diseases of the Skin.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of stent implantation and glycoprotein IIb/IIIa receptor blockade on TIMI flow and mortality after primary PTCA in acute myocardial infarction: Final results of the CADILLAC trial Cindy L. Grines, David A. Cox, James E. Tcheng, Eulogio Garcia, Thomas Stuckey, John Carroll, Giulio Guagliumi, Barry Rutherford, Paolo Esente, Alexandra J. Lansky, John Griffin, Gregg W. Stone. The Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, New York City, NY, William …
Journal: Journal of the American College of Cardiology (2001)
Circulating tumor DNA dynamics on front-line chemotherapy with bevacizumab or cetuximab in metastatic colorectal cancer: A biomarker analysis for acquired genomic alterations in CALGB/SWOG 80405 (Alliance) randomized trial.
Authors: Kanwal Pratap Singh Raghav, Fang-Shu Ou, Alan P. Venook, Federico Innocenti, Ryan Sun, Heinz-Josef Lenz, Scott Kopetz
Journal: Journal of Clinical Oncology (2022)

193 Background: Enhanced understanding of the evolving clonal architecture under treatment stress is crucial to optimizing care and developing effective therapies in metastatic colorectal cancer (mCRC). Emergence of genomic alterations (GAs) [mutations (muts) and amplifications (amps)] in RAS, BRAF, EGFR, ERBB2, and MET have been recognized as key resistance mechanisms to anti-EGFR therapy in later lines in mCRC. Data regarding occurrence of these GAs under selective pressure in the first line setting is lacking. Methods: CALGB/SWOG 80405 was a randomized trial of bevacizumab (bev) vs cetuximab (cet) in first line mCRC. Patients (pts) with paired plasma samples (pre-treatment and post-progression) available for circulating tumor DNA (ctDNA) testing were included in this substudy. Sequencing of ctDNA was performed by Guardant360 assay in a CLIA-certified environment to detect GAs in 73 genes. RAS/BRAF status [mut vs. wild type (wt)] was based on clonal muts [pre-defined cutoff of relative MAF (rMAF) ≥ 25%] in ctDNA. Only samples with ≥1 GA were analyzed to minimize false negatives. The primary objective was to determine and compare prevalence of acquired GAs between study arms: bev (anti-VEGF) and cet (anti-EGFR). Descriptive statistics and Fisher’s exact test were used. Results: Baseline characteristics of ctDNA cohort were similar to the 80405 population. Among 133 randomized RAS/BRAF wt pts, 11 (15.3%) and 5 (8.2%) developed acquired GAs (OR 2.0, P = 0.29), in bev and cet arm, respectively. Key comparative data for pts with regard to acquired pathogenic GAs are shown in the table. Conclusions: In this randomized mCRC cohort, the ctDNA profile of acquired GAs with front line anti-EGFR chemotherapy appears to be strikingly distinct from that seen with later lines of therapy. Acquisition of GAs, classically associated with EGFR resistance in later line, was not only rare with upfront cet-chemotherapy but also comparable to bev-containing (anti-VEGF) regimen. The mechanisms of acquired resistance appear to differ when anti-EGFR therapy is administered in combination with highly active first line chemotherapy. Our findings have critical translational relevance to the timing and value of ctDNA-guided anti-EGFR rechallenge in mCRC pts, especially in those treated with anti-EGFR therapy upfront.[Table: see text]
Family practice undergraduate education
Authors: G. S. Walbroehl
Journal: JAMA (1981)

A survey conducted by the Wright State University School of Medicine indicates that family practice has become a fully integrated curriculum component in the majority of US medical schools. Results indicate that family practice courses are offered most often as outpatient experiences and are taught by both full-time and volunteer faculty. (<i>JAMA</i>1981;245:1552-1553)
Amputations. Operative Technique—Formation and After-Treatment of the Stump from the Standpoint of Prosthesis. A Study Based on Seventeen Hundred Cases of Amputation for Injuries and Disease Occurring in the World War and Since Its Termination. Published under the authority and with the approval of the Surgeon General, U. S. Army.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Department of Error
Journal: The Lancet (2020)

in blood pressure; however, enabling the safer use of spironolactone was the necessary first step towards designing an outcomes trial.The ongoing DIAMOND (NCT03888066) randomised trial builds on our findings.The trial of nearly 2400 study participants will examine the safety and efficacy of patiromer enablement of spironolactone for cardiovascular death or hospitalisation.DIAMOND will definitively answer the important question regarding costs and benefits of patiromer therapy to enable spiro nolactone use in patients at a high risk of cardiovascular events.
Holiday typhoid.
Authors: Briti Sh
Journal: BMJ (1969)

Pointers Sodium Reabsorption: The first part of Profes- sor H. E. de Wardener's Oliver-Sharpey lecture to the Royal College of Physicians of London (p.611).Juvenile Diabetes: Results of a prospective 10- year comparison of corn-oil and standard diets suggest that latter can maintain normal serum lipid levels in most adequately controlled diabetic children (p.616).Fluid Therapy during Surgery: A clinical study suggests that excess Ringer-lactate solution given during surgery may not be excreted and that overtransfusion can easily occur (p.619).Entrapment Neuropathy: Series of 23 patients with entrapment neuropathy of the common peroneal nerve (p.623).Diabetes and Viruses: Insulin-dependent diabetics within three months of onset were found to have raised antibody titres to Coxsackie B virus (p.627).There was some correlation between 'the numbers of new cases of diabetes and the annual prevalence of Coxsackie B4 infections (p.631).Psychotropic Drugs and Chromosomes: Patients being treated with perphenazine and lysergide had more chromosome abnormalities than controls (p.634).Short Reports: Neonatal pulmonary haemor- rhage and Coxsackie B infection (p.636).Chicken-pox pneumonitis (p.637).Practical Neurology: New refresher course series.First article is on diagnosis and manage- ment of muscular dystrophies (p.639).Unattended Confinement: Analysis of 100 con- secutive cases (p.646).Thomas Willis: His birthplace (p.648).